Dr Bernard Vrijens
Chief Executive Officer & Scientific Lead

About

Bernard Vrijens, PhD, Chief Executive Officer and Scientific Lead, AARDEX Group and Invited Professor of Biostatistics, Liège University, Belgium, holds a PhD from the Department of Applied Mathematics and Informatics at Ghent University, Belgium.

Dr Vrijens currently leads a research programme investigating (a) the most common errors in dosing using a simple but robust taxonomy, (b) particular dosing errors that can jeopardise the efficacy of a drug and (c) the optimal measurement-guided medication management programme that can enhance adherence to medications and maintain long-term persistence.

Dr Vrijens is also the co-author of seven book chapters, over 100 peer-reviewed scientific papers and named as inventor on six patents. He is a founding member of the International Society for Medication Adherence (ESPACOMP), and an active member of several EU- and US-funded collaborative projects around the theme of adherence to medications.

Contributions

CONNECTIVITY

SMART MEMS CAP FOR SHARPS WASTE: A SIMPLE AND ELEGANT SOLUTION TO CLINICAL TRIAL ADHERENCE MONITORING

Frank Leipold and Bernard Vrijens discuss Haselmeier & AARDEX’ s collaboration to develop the MEMS Smart Cap – a smart solution for data collection during clinical trials to enable an accurate assessment of participant nonadherence.

More contributions

EXPERT VIEW

FOCUS ON ADHERENCE TO EMBRACE DCT BENEFITS

Bernard Vrijens looks at the effect of decentralised clinical trials on medication adherence in clinical studies.

CONNECTIVITY

MEASURING & MANAGING MEDICATION ADHERENCE FROM CLINICAL TRIALS TO ROUTINE CARE: INJAY MEMS AS^®

Arnaud Guillet and Bernard Vrijens discuss the issue of medication non-adherence in both clinical trials and commercialised drug products, and how Biocorp’s Injay connected prefilled syringe solution combined with Aardex’s MEMS Adherence Software provides a solution.